PHIL Stock Overview
Develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Philadelphia Pharmaceuticals Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | د.أ1.45 |
52 Week High | د.أ1.54 |
52 Week Low | د.أ1.35 |
Beta | 0.031 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 7.41% |
33 Year Change | 3.57% |
5 Year Change | -11.59% |
Change since IPO | 108.33% |
Recent News & Updates
Recent updates
Shareholder Returns
PHIL | JO Pharmaceuticals | JO Market | |
---|---|---|---|
7D | -5.8% | -1.4% | -0.5% |
1Y | 7.4% | 4.6% | -2.7% |
Return vs Industry: PHIL exceeded the JO Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: PHIL exceeded the JO Market which returned -2.7% over the past year.
Price Volatility
PHIL volatility | |
---|---|
PHIL Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 3.9% |
10% most volatile stocks in JO Market | 5.9% |
10% least volatile stocks in JO Market | 1.8% |
Stable Share Price: PHIL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHIL's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 133 | Ashraf Ahmad Hussein | www.philapharma.com |
Philadelphia Pharmaceuticals Company develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan. The company provides products for skin related disorders, including anti-lice and scabicides preparations, antiseptics and disinfectants, bleaching and hyperpigmentation disorders preparations, emollients and protectives, keratolytics/topical psoriasis treatment preparations, and skin healing agents, as well as agents for dermatitis; and topical acne preparation, anti-pruritic, anti-viral, plain antifungal and anti-infective, plain steroid, steroids with antifungal/anti-infective combination, and skin recoloring products. It also offers products for women health, such as vaginal antifungals, alkalinizing and cleansing agents, antimicrobials, germicidal fungicidal, antiseptics and hemostatic, and vaginal progesterone; and products in the areas of alimentary, gastrointestinal system, anti-inflammatory, analgesic, antipyretic, dental-oropharyngeal, hair care, local anesthetics, and respiratory system, as well as supplements and health care-OTC products.
Philadelphia Pharmaceuticals Company Fundamentals Summary
PHIL fundamental statistics | |
---|---|
Market cap | د.أ10.88m |
Earnings (TTM) | د.أ831.25k |
Revenue (TTM) | د.أ8.72m |
13.1x
P/E Ratio1.2x
P/S RatioIs PHIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHIL income statement (TTM) | |
---|---|
Revenue | د.أ8.72m |
Cost of Revenue | د.أ4.65m |
Gross Profit | د.أ4.07m |
Other Expenses | د.أ3.24m |
Earnings | د.أ831.25k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.11 |
Gross Margin | 46.66% |
Net Profit Margin | 9.53% |
Debt/Equity Ratio | 19.2% |
How did PHIL perform over the long term?
See historical performance and comparison